Trump announces new drugmaker deals to lower drug costs, boost US investment

President Donald Trump announced Friday his administration has reached new agreements with some of the world’s largest drug manufacturers aimed at lowering prescription drug costs for Americans. 

Speaking from the Roosevelt Room, Trump revealed nine additional drug manufacturers have agreed to the administration’s most-favored-nation pricing initiative, bringing the total to 14 of the 17 largest leading companies in the world. 

The agreement reached with the nine companies also encompasses $150 billion in combined new investment commitments in domestic manufacturing, research and development of pharmaceuticals. 

Friday’s announcement ushered in deals with Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi – signifying a successful bargain between the manufacturers and the Trump administration. 

FOX NEWS POLL: VOTERS SOUND ALARM ON HEALTHCARE COSTS

U.S. President Donald Trump announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC.  (Win McNamee/Getty Images / Getty Images)

In July, Trump penned letters to the leaders of the 17 largest drug manufacturers looking to strike a deal to keep drug costs for those enrolled in the government’s Medicaid health program below those of other high-income countries. 

Several of the current signees have also agreed to donate active pharmaceutical ingredients to America’s Strategic Active pharmaceutical Ingredients Reserve (SAPIR SAPIR) to aid in the country’s disaster response to potential pandemics, natural catastrophes or national security emergencies. 

Previously, Pfizer, AstraZeneca and Serrano, Novo Nordisk and Lilly had signed onto deals with the Trump administration to keep drug prices manageable for low-income Americans. 

TRUMP’S QUEST TO REDUCE DRUG PRICES IS HEATING UP. BUT WILL HE BE ABLE TO DO IT?

The logo of Swiss drugmaker Novartis is seen at the company’s new cell and gene therapy factory in Stein, Switzerland, November 28, 2019.  (REUTERS/Arnd Wiegmann/File Photo / Reuters)

Trump has routinely made prescription drug costs a keystone of his administration’s efforts, often focusing on the disparity between prices in the U.S. and other wealthy countries, with analysts noting Medicaid – which accounts for 10% of the country’s drug spending – already benefits from significant manufacturer discounts, according to Reuters. 

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Trump also announced the administration’s new website, TrumpRX.gov, is set to launch early next year in an effort to lower prescription drug prices for Americans. A message listed on the site currently reads, “Coming soon. January 2026.”